What Happened?
San Diego, -based Odonate Resigned Chase Leavitt as Vice President of Legal Affairs
About the Company
Odonate Therapeutics™ is dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, an investigational, orally administered taxane. We are conducting our multinational, multicenter, randomized, Phase 3 study in locally advanced or metastatic breast cancer (MBC), known as CONTESSA. Our goal is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.
About the Person
Chase Leavitt is General Counsel at Oncternal. Previously, Chase held various senior legal leadership roles in the industry.
Info Source
News
Short Profile